Stockscreener 앱 받기
220.43
0.80%
1.76
시간 외 거래:
219.41
-1.02
-0.46%
전일 마감가:
$218.67
열려 있는:
$218
하루 거래량:
7.79M
Relative Volume:
1.29
시가총액:
$389.58B
수익:
$59.64B
순이익/손실:
$2.36B
주가수익비율:
166.32
EPS:
1.3253
순현금흐름:
$19.68B
1주 성능:
+1.06%
1개월 성능:
-4.51%
6개월 성능:
+15.28%
1년 성능:
+25.77%
1일 변동 폭
$218.00
$224.14
1주일 범위
$215.88
$226.86
52주 변동 폭
$164.39
$244.81
애브비 Stock (ABBV) Company Profile
명칭
Abbvie Inc
전화
(847) 932-7900
주소
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
ABBV을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
220.43 | 386.47B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
LLY
Lilly Eli Co
|
1,024.14 | 916.32B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
227.29 | 548.64B | 94.19B | 26.80B | 20.46B | 11.05 |
|
NVS
Novartis Ag Adr
|
148.91 | 283.73B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
108.34 | 265.33B | 63.90B | 19.05B | 13.05B | 7.5596 |
애브비 Stock (ABBV) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-08 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2026-01-07 | 재개 | UBS | Neutral |
| 2025-12-10 | 업그레이드 | HSBC Securities | Hold → Buy |
| 2025-11-13 | 개시 | Scotiabank | Sector Outperform |
| 2025-11-04 | 다운그레이드 | DZ Bank | Buy → Hold |
| 2025-10-14 | 다운그레이드 | Erste Group | Buy → Hold |
| 2025-10-01 | 다운그레이드 | HSBC Securities | Buy → Hold |
| 2025-09-17 | 업그레이드 | Berenberg | Hold → Buy |
| 2025-08-12 | 재개 | Piper Sandler | Overweight |
| 2025-08-07 | 업그레이드 | Daiwa Securities | Neutral → Outperform |
| 2025-05-14 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2025-04-22 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-12-10 | 재개 | BofA Securities | Neutral |
| 2024-12-05 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2024-11-22 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-11-15 | 개시 | Wolfe Research | Outperform |
| 2024-11-04 | 업그레이드 | Argus | Hold → Buy |
| 2024-10-17 | 개시 | Bernstein | Mkt Perform |
| 2024-06-05 | 업그레이드 | HSBC Securities | Hold → Buy |
| 2024-05-17 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-01-29 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2023-12-18 | 다운그레이드 | HSBC Securities | Buy → Hold |
| 2023-12-11 | 업그레이드 | Goldman | Neutral → Buy |
| 2023-11-09 | 개시 | Deutsche Bank | Hold |
| 2023-10-30 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2023-10-20 | 재개 | UBS | Neutral |
| 2023-09-29 | 개시 | Raymond James | Outperform |
| 2023-07-25 | 개시 | William Blair | Mkt Perform |
| 2023-07-14 | 개시 | HSBC Securities | Buy |
| 2023-04-05 | 다운그레이드 | Argus | Buy → Hold |
| 2023-03-01 | 개시 | Guggenheim | Buy |
| 2023-02-22 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2023-02-10 | 업그레이드 | SVB Securities | Underperform → Market Perform |
| 2022-11-18 | 개시 | Credit Suisse | Outperform |
| 2022-11-08 | 다운그레이드 | Societe Generale | Buy → Hold |
| 2022-08-01 | 다운그레이드 | Atlantic Equities | Overweight → Neutral |
| 2022-05-23 | 개시 | SVB Leerink | Underperform |
| 2022-05-06 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2022-04-06 | 재개 | Morgan Stanley | Overweight |
| 2022-02-28 | 다운그레이드 | UBS | Buy → Neutral |
| 2022-02-03 | 재확인 | BMO Capital Markets | Outperform |
| 2022-02-03 | 재확인 | Barclays | Equal Weight |
| 2022-02-03 | 재확인 | BofA Securities | Neutral |
| 2022-02-03 | 재확인 | Goldman | Neutral |
| 2022-01-13 | 개시 | Redburn | Buy |
| 2022-01-12 | 재확인 | BMO Capital Markets | Outperform |
| 2021-12-09 | 재개 | Wells Fargo | Overweight |
| 2021-11-23 | 업그레이드 | Societe Generale | Hold → Buy |
| 2021-07-27 | 재개 | Truist | Buy |
| 2021-04-07 | 재개 | RBC Capital Mkts | Outperform |
| 2020-11-10 | 재개 | Bernstein | Outperform |
| 2020-09-29 | 개시 | Berenberg | Hold |
| 2020-06-23 | 업그레이드 | Atlantic Equities | Neutral → Overweight |
| 2020-06-09 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2020-06-02 | 업그레이드 | Argus | Hold → Buy |
| 2020-05-18 | 재개 | BofA/Merrill | Neutral |
| 2020-05-12 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2020-05-11 | 재개 | Morgan Stanley | Overweight |
| 2020-04-20 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-03-23 | 다운그레이드 | Societe Generale | Buy → Hold |
| 2020-02-27 | 개시 | Barclays | Equal Weight |
| 2020-02-06 | 개시 | Mizuho | Buy |
| 2020-01-07 | 개시 | RBC Capital Mkts | Sector Perform |
| 2019-12-26 | 재확인 | Cowen | Outperform |
| 2019-09-26 | 업그레이드 | Citigroup | Neutral → Buy |
| 2019-08-20 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2019-06-27 | 업그레이드 | Wolfe Research | Underperform → Peer Perform |
| 2019-06-26 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2019-05-28 | 개시 | Goldman | Neutral |
| 2019-04-29 | 업그레이드 | BMO Capital Markets | Underperform → Market Perform |
모두보기
애브비 주식(ABBV)의 최신 뉴스
Spinal Cord Injury Market to Evolve Rapidly Over the Next Decade by 2034, DelveInsight Observes | Kringle Pharma, Neuroplast, AbbVie, and Mitsubishi Tanabe Pharma America - Barchart.com
AbbVie Launches Love in Mind to Spotlight the Emotional Impact of Migraine on Romantic Relationships - Investing News Network
3 in 4 with migraine say attacks hurt their romantic lives - Stock Titan
Spinal Cord Injury Market: Growth Momentum Across 7MM to 2034 – DelveInsight | Kringle Pharma, Neuroplast, Abbvie, Mitsubishi Tanabe Pharma, Lineage Cell Therapeutics, NervGen Pharma - Barchart.com
AbbVie (ABBV) Dips More Than Broader Market: What You Should Know - Yahoo Finance
Why AbbVie Stock Trounced the Market in 2025 - Finviz
Aldeyra’s Dry Eye Drug Faces A Make-Or-Break FDA Call - Finimize
Taking The First Steps Towards Digitalizing Biopharma Development - Bioprocess Online
UnitedHealth Flags Margin Stress, Pushing Investors Toward Broader Healthcare ETFs - Benzinga
AbbVie's Irish operations in firing line as Trump targets Botox prices - Irish Examiner
AbbVie (ABBV) Reports Next Week: Wall Street Expects Earnings Growth - Nasdaq
AbbVie Partners with Trump Administration to Enhance Access and Affordability - Intellectia AI
AbbVie, SLB, Amphenol, And More On CNBC's 'Final Trades' - Benzinga
Medicare Targets 15 High-Profile Drugs In Third Price Negotiation Cycle - Benzinga
Q3 Earnings Highs And Lows: AbbVie (NYSE:ABBV) Vs The Rest Of The Therapeutics Stocks - Finviz
CMS Names Pfizer, Eli Lilly, and AbbVie Drugs for Third Medicare Price Talks - TipRanks
Does AbbVie's Bispecific Trial Win and R&D Pledge Change The Bull Case For AbbVie (ABBV)? - Yahoo Finance
US names Eli Lilly, Pfizer and AbbVie drugs for next Medicare price talks - wkzo.com
US Medicare names Eli Lilly, Pfizer and AbbVie drugs for next Medicare price talks - Yahoo! Finance Canada
Eli Lilly, Pfizer, AbbVie drugs targeted in third Medicare price talks - Investing.com Canada
AbbVie stock rises as insurers crater and the Fed week kicks off - TechStock²
Citigroup Issues Pessimistic Forecast for AbbVie (NYSE:ABBV) Stock Price - MarketBeat
Citigroup Adjusts Price Target for AbbVie (ABBV) to $230, Mainta - GuruFocus
Atopic Dermatitis Market to Reach USD 12.97 Billion by 2034, Growing at 7.75% CAGR - GlobeNewswire Inc.
Is the Options Market Predicting a Spike in AbbVie Stock? - TradingView
J. Safra Sarasin Holding AG Purchases 62,723 Shares of AbbVie Inc. $ABBV - MarketBeat
Berenberg Grows More Confident in AbbVie (ABBV) on Skyrizi and Rinvoq Momentum - Finviz
AbbVie stock price closes higher; what to watch next for ABBV ahead of Fed week and earnings - TechStock²
AbbVie stock price edges up: what investors watch ahead of Feb. 4 earnings - TechStock²
How Recent Price Target Rethinks Are Rewriting The Story For AbbVie (ABBV) - Yahoo Finance
AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Vanguard Personalized Indexing Management LLC Increases Stock Position in AbbVie Inc. $ABBV - MarketBeat
AbbVie Inc. $ABBV Shares Sold by Parthenon LLC - MarketBeat
AbbVie Inc. $ABBV Stake Cut by Lbp Am Sa - MarketBeat
AbbVie Inc. $ABBV Position Cut by Mutual of America Capital Management LLC - MarketBeat
Corticosteroids Market Report 2026 - GlobeNewswire Inc.
AEGON ASSET MANAGEMENT UK Plc Decreases Stock Position in AbbVie Inc. $ABBV - MarketBeat
AbbVie Inc. (ABBV): Investor Outlook and Potential 11.84% Upside with Strong Analyst Support - DirectorsTalk Interviews
Commerzbank Aktiengesellschaft FI Sells 39,586 Shares of AbbVie Inc. $ABBV - MarketBeat
Cullen Frost Bankers Inc. Has $88.49 Million Holdings in AbbVie Inc. $ABBV - MarketBeat
West to Sell SmartDose 3.5mL System to AbbVie in $112.5M Deal - mychesco.com
AbbVie is a top dividend stock as drug pipelines drive payout hikes - thestreet.com
Mn Services Vermogensbeheer B.V. Has $155.25 Million Position in AbbVie Inc. $ABBV - MarketBeat
Resona Asset Management Co. Ltd. Decreases Stock Holdings in AbbVie Inc. $ABBV - MarketBeat
Mitsubishi UFJ Trust & Banking Corp Sells 18,081 Shares of AbbVie Inc. $ABBV - MarketBeat
UniSuper Management Pty Ltd Has $58.21 Million Holdings in AbbVie Inc. $ABBV - MarketBeat
AbbVie Inc. $ABBV Shares Purchased by Jennison Associates LLC - MarketBeat
Delta Financial Advisors LLC Purchases 4,830 Shares of AbbVie Inc. $ABBV - MarketBeat
TrueMark Investments LLC Lowers Position in AbbVie Inc. $ABBV - MarketBeat
AbbVie stock rises as India rejects Venetoclax patent bid; ABBV traders eye Feb. 4 earnings - TechStock²
AbbVie Inc. $ABBV Shares Sold by Lockheed Martin Investment Management Co. - MarketBeat
애브비 (ABBV) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.70%
1.66%
자본화:
|
볼륨(24시간):